Ionis' partner Biogen provides update on tofersen Phase 3 VALOR study in SOD1-ALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 5/24/2022
- Wall Street rallies on back of big tech, banks
- 'Snap Drops a Bomb': Snap (SNAP) Stock Crashes Nearly 30% on Forecast Cut, Musk-Twitter Saga to Get a 'Whole Lot More Interesting' Says Analyst
- Zoom (ZM) Stock Surges on Better-than-feared Results and Guidance, Analysts Positive
- Wall Street Positive on Broadcom's (AVGO) Potential $60 Billion Deal for VMWare (VMW)
- Snap Shares Plunge 25% on Q2 Warning
- Cosan's (CSAN) Moove Acquires PetroChoice from Golden Gate Capital for $479M
- DexCom (DXCM) is in talks to acquire Insulet (PODD) - Bloomberg
- UPDATE: Snap (SNAP) warns for Q2
- AMD (AMD) Stock Could Rally Over 70% Says BofA, Analyst Sees Multiple Catalysts Ahead
- Morgan Stanley's Wilson Expects S&P 500 to Hit 3400 by End of Q2 Earning Season, Says Fed Put is Below 3500
- After-Hours Stock Movers 05/23: Snap's Warning Sends Shivers Throughout Tech; Zoom Gains on Results (more...)
- Pre-Open Stock Movers 05/23: VMware Surges on Possible Broadcom Takeover; Retails Stocks Sick Again on Downgrades (more...)
- Pre-Open Stock Movers 05/20: Deckers, Palo Alto Jump on Results; Ross Stores Sinks (more...)
- Companies with NDRs 5/20
- After-Hours Stock Movers 05/19: Palo Alto Ramps on Strong Results; Ross Stores Plunges (more...)
Ionis Pharmaceuticals (IONS) PT Lowered to $68 at Laidlaw
October 18, 2021 7:53 AM EDTLaidlaw analyst Yale Jen lowered the price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $68.00 (from $78.00) while maintaining a Buy rating.
Tofersen in SOD1-ALS VALOR Trial Failed to Meet Primary Endpoint but Substantial Knowledge Learned... More
